
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor&#8208;positive, HER2&#8208;negative metastatic breast cancer: A real&#8208;world multicenter study - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="322C300B24F39205000051774852D4F5.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="canmed" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC10923034/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923034/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Cancer Medicine" /><meta name="citation_title" content="Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor&#x02010;positive, HER2&#x02010;negative metastatic breast cancer: A real&#x02010;world multicenter study" /><meta name="citation_author" content="Doudou Li" /><meta name="citation_author_institution" content="Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai China" /><meta name="citation_author_institution" content="Department of Oncology, Shanghai Medical College, Fudan University, Shanghai China" /><meta name="citation_author" content="Yizi Jin" /><meta name="citation_author_institution" content="Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai China" /><meta name="citation_author_institution" content="Department of Oncology, Shanghai Medical College, Fudan University, Shanghai China" /><meta name="citation_author" content="Mingxi Lin" /><meta name="citation_author_institution" content="Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai China" /><meta name="citation_author_institution" content="Department of Oncology, Shanghai Medical College, Fudan University, Shanghai China" /><meta name="citation_author" content="Cheng Zeng" /><meta name="citation_author_institution" content="Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai China" /><meta name="citation_author_institution" content="Department of Oncology, Shanghai Medical College, Fudan University, Shanghai China" /><meta name="citation_author" content="Qing Guo" /><meta name="citation_author_institution" content="Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai China" /><meta name="citation_author_institution" content="Department of Oncology, Shanghai Medical College, Fudan University, Shanghai China" /><meta name="citation_author" content="Yanfei Liu" /><meta name="citation_author_institution" content="Department of Oncology, Shanghai Medical College, Fudan University, Shanghai China" /><meta name="citation_author_institution" content="MN. Office of Clinical Research, Fudan University Shanghai Cancer Center, Shanghai China" /><meta name="citation_author" content="Jian Zhang" /><meta name="citation_author_institution" content="Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai China" /><meta name="citation_author_institution" content="Department of Oncology, Shanghai Medical College, Fudan University, Shanghai China" /><meta name="citation_author_institution" content="Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai China" /><meta name="citation_publication_date" content="2024/02" /><meta name="citation_issue" content="4" /><meta name="citation_volume" content="13" /><meta name="citation_doi" content="10.1002/cam4.6762" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC10923034/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC10923034/" /><meta name="citation_pmid" content="38457252" /><meta name="DC.Title" content="Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor&#x02010;positive, HER2&#x02010;negative metastatic breast cancer: A real&#x02010;world multicenter study" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Wiley" /><meta name="DC.Contributor" content="Doudou Li" /><meta name="DC.Contributor" content="Yizi Jin" /><meta name="DC.Contributor" content="Mingxi Lin" /><meta name="DC.Contributor" content="Cheng Zeng" /><meta name="DC.Contributor" content="Qing Guo" /><meta name="DC.Contributor" content="Yanfei Liu" /><meta name="DC.Contributor" content="Jian Zhang" /><meta name="DC.Date" content="2024 Feb" /><meta name="DC.Identifier" content="10.1002/cam4.6762" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor&#x02010;positive, HER2&#x02010;negative metastatic breast cancer: A real&#x02010;world multicenter study" /><meta property="og:type" content="article" /><meta property="og:description" content="Chidamide is a selective histone deacetylase inhibitor approved for patients with hormone receptor (HoR)&#x02010;positive and HER2&#x02010;negative metastatic breast cancer (MBC). We aimed to investigate the efficacy, safety, and treatment patterns of ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923034/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10923034/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/1974/">Cancer Med</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/457477/">v.13(4); 2024 Feb</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10923034
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10923034/pdf/CAM4-13-e6762.pdf" class="int-view">PDF (1.0M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10923034/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10923034/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10923034" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10923034%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="IrYGrKVQXU9T6cDP4tq2f6PgWt6nZdM2DZR6b2YC9oJy9keLfJ7Qd2vOCRmaFKKc">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10923034%2F&amp;text=Treatment%20patterns%20and%20clinical%20outcomes%20of%20chidamide%20combined%20with%20endocrine%20therapy%20in%20hormone%20receptor%02010positive%2C%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10923034%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923034/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10923034/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/38457252/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10923034/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/38457252/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10923034/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10923034/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/1974/">Cancer Med</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/457477/">v.13(4); 2024 Feb</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10923034
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-canmed.gif" alt="Logo of canmed" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2045-7634" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Cancer Med.</span> 2024 Feb; 13(4): e6762. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2024 Mar 8. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1002%2Fcam4.6762" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1002/cam4.6762</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC10923034</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/38457252">38457252</a></div></div></div><h1 class="content-title">Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor&#x02010;positive, <span style="fixed-case">HER2</span>&#x02010;negative metastatic breast cancer: A real&#x02010;world multicenter study</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Li%20D%5BAuthor%5D" id="cam46762-cr-0001" class="affpopup" co-rid="_co_idm139793803868352" co-class="co-affbox">Doudou Li</a>,<sup>
1
,</sup><sup>
2
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Jin%20Y%5BAuthor%5D" id="cam46762-cr-0002" class="affpopup" co-rid="_co_idm139793803864624" co-class="co-affbox">Yizi Jin</a>,<sup>
1
,</sup><sup>
2
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Lin%20M%5BAuthor%5D" id="cam46762-cr-0003" class="affpopup" co-rid="_co_idm139793803860896" co-class="co-affbox">Mingxi Lin</a>,<sup>
1
,</sup><sup>
2
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zeng%20C%5BAuthor%5D" id="cam46762-cr-0004" class="affpopup" co-rid="_co_idm139793779321376" co-class="co-affbox">Cheng Zeng</a>,<sup>
1
,</sup><sup>
2
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Guo%20Q%5BAuthor%5D" id="cam46762-cr-0005" class="affpopup" co-rid="_co_idm139793779317648" co-class="co-affbox">Qing Guo</a>,<sup>
1
,</sup><sup>
2
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Liu%20Y%5BAuthor%5D" id="cam46762-cr-0006" class="affpopup" co-rid="_co_idm139793779411504" co-class="co-affbox">Yanfei Liu</a>,<sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>
2
,</sup><sup>
3
</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20J%5BAuthor%5D" id="cam46762-cr-0007" class="affpopup" co-rid="_co_idm139793779407152" co-class="co-affbox">Jian Zhang</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>
1
,</sup><sup>
2
,</sup><sup>
4
</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139793803868352"><h3 class="no_margin">Doudou Li</h3><p>
<sup>
1
</sup>
Department of Medical Oncology, 
Fudan University Shanghai Cancer Center, 
Shanghai
China
</p><p>
<sup>
2
</sup>
Department of Oncology, 
Shanghai Medical College, Fudan University, 
Shanghai
China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Li%20D%5BAuthor%5D">Doudou Li</a></div></div><div id="_co_idm139793803864624"><h3 class="no_margin">Yizi Jin</h3><p>
<sup>
1
</sup>
Department of Medical Oncology, 
Fudan University Shanghai Cancer Center, 
Shanghai
China
</p><p>
<sup>
2
</sup>
Department of Oncology, 
Shanghai Medical College, Fudan University, 
Shanghai
China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Jin%20Y%5BAuthor%5D">Yizi Jin</a></div></div><div id="_co_idm139793803860896"><h3 class="no_margin">Mingxi Lin</h3><p>
<sup>
1
</sup>
Department of Medical Oncology, 
Fudan University Shanghai Cancer Center, 
Shanghai
China
</p><p>
<sup>
2
</sup>
Department of Oncology, 
Shanghai Medical College, Fudan University, 
Shanghai
China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Lin%20M%5BAuthor%5D">Mingxi Lin</a></div></div><div id="_co_idm139793779321376"><h3 class="no_margin">Cheng Zeng</h3><p>
<sup>
1
</sup>
Department of Medical Oncology, 
Fudan University Shanghai Cancer Center, 
Shanghai
China
</p><p>
<sup>
2
</sup>
Department of Oncology, 
Shanghai Medical College, Fudan University, 
Shanghai
China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zeng%20C%5BAuthor%5D">Cheng Zeng</a></div></div><div id="_co_idm139793779317648"><h3 class="no_margin">Qing Guo</h3><p>
<sup>
1
</sup>
Department of Medical Oncology, 
Fudan University Shanghai Cancer Center, 
Shanghai
China
</p><p>
<sup>
2
</sup>
Department of Oncology, 
Shanghai Medical College, Fudan University, 
Shanghai
China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Guo%20Q%5BAuthor%5D">Qing Guo</a></div></div><div id="_co_idm139793779411504"><h3 class="no_margin">Yanfei Liu</h3><p>
<sup>
2
</sup>
Department of Oncology, 
Shanghai Medical College, Fudan University, 
Shanghai
China
</p><p>
<sup>
3
</sup>
MN. Office of Clinical Research, 
Fudan University Shanghai Cancer Center, 
Shanghai
China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Liu%20Y%5BAuthor%5D">Yanfei Liu</a></div></div><div id="_co_idm139793779407152"><h3 class="no_margin">Jian Zhang</h3><p>
<sup>
1
</sup>
Department of Medical Oncology, 
Fudan University Shanghai Cancer Center, 
Shanghai
China
</p><p>
<sup>
2
</sup>
Department of Oncology, 
Shanghai Medical College, Fudan University, 
Shanghai
China
</p><p>
<sup>
4
</sup>
Phase I Clinical Trial Center, 
Fudan University Shanghai Cancer Center, 
Shanghai
China
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20J%5BAuthor%5D">Jian Zhang</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm139793778545136_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139793778545136_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139793778545136_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm139793778545136_ai" style="display:none"><div class="fm-affl" id="cam46762-aff-0001">
<sup>
1
</sup>
Department of Medical Oncology, 
Fudan University Shanghai Cancer Center, 
Shanghai
China
</div><div class="fm-affl" id="cam46762-aff-0002">
<sup>
2
</sup>
Department of Oncology, 
Shanghai Medical College, Fudan University, 
Shanghai
China
</div><div class="fm-affl" id="cam46762-aff-0003">
<sup>
3
</sup>
MN. Office of Clinical Research, 
Fudan University Shanghai Cancer Center, 
Shanghai
China
</div><div class="fm-affl" id="cam46762-aff-0004">
<sup>
4
</sup>
Phase I Clinical Trial Center, 
Fudan University Shanghai Cancer Center, 
Shanghai
China
</div><div><span class="fm-affl">Yanfei Liu, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="nc.ude.naduf@iefnayuil" class="oemail">nc.ude.naduf@iefnayuil</a></span>.</div><div><a href="#cam46762aff-info">Contributor Information</a>.</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><div id="correspondenceTo"><sup>*</sup>

<strong>Correspondence</strong>
<br />
Jian Zhang, Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270, Dong An Road, Shanghai 200032, China.<br />
Email: <a href="mailto:dev@null" data-email="moc.361@0002renys" class="oemail">moc.361@0002renys</a>
<br />
Yanfei Liu, MN. Office of Clinical Research, Fudan University Shanghai Cancer Center, 270, Dong An Road, Shanghai 200032, China.<br />
Email: <a href="mailto:dev@null" data-email="nc.ude.naduf@iefnayuil" class="oemail">nc.ude.naduf@iefnayuil</a>
<br />
</div></div><div class="fm-article-notes hide half_rhythm" id="idm139793778545136_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2023 Jun 18; Revised 2023 Oct 29; Accepted 2023 Nov 13.</div></div><div class="permissions half_rhythm hide" id="idm139793778545136_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; 2024 The Authors. <em>Cancer Medicine</em> published by John Wiley &#x00026; Sons Ltd.</div><div class="license half_rhythm">This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">http://creativecommons.org/licenses/by/4.0/</a> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-length="117" class="box-data-avail whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-avl-stmnt" data-ga-action="click_feat_toggler" data-ga-label="Data Availability Statement" class="pmctoggle">Data Availability Statement</a></dt><dd id="data-avl-stmnt" style="display: none;"><p class="p p-first-last">The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></dd></dl></div><div id="abstract-a.n.b.u" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.n.b.utitle">Abstract</h2><!--article-meta--><div><div id="cam46762-sec-0001" class="sec sec-first"><h3 id="cam46762-sec-0001title">Background</h3><p class="p p-first-last">Chidamide is a selective histone deacetylase inhibitor approved for patients with hormone receptor (HoR)&#x02010;positive and HER2&#x02010;negative metastatic breast cancer (MBC). We aimed to investigate the efficacy, safety, and treatment patterns of chidamide and identify clinicopathological factors that predict the efficacy of chidamide in real&#x02010;world scenarios.</p></div><div id="cam46762-sec-0002" class="sec"><h3 id="cam46762-sec-0002title">Methods</h3><p class="p p-first-last">Consecutive MBC patients treated with chidamide from January 2020 to August 2021 across 11 institutions were enrolled in this multicenter, retrospective study. Eligible patients were pre&#x02010; and postmenopausal women who had clinically or histologically confirmed ER&#x02010;positive, HER2&#x02010;negative MBC, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients with multiple primary malignancies or missing baseline characteristics were excluded. Patients received 30&#x02009;mg chidamide orally twice a week, combined with aromatase inhibitors (AIs) or non&#x02010;AIs. Efficacy analyses included progression&#x02010;free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR). Univariate and multivariate Cox regression analyses were performed to identify the potential efficacy predictors.</p></div><div id="cam46762-sec-0003" class="sec"><h3 id="cam46762-sec-0003title">Results</h3><p class="p p-first-last">A total of 157 patients were finally included for analysis. The median number of lines prior to chidamide was four. In the whole cohort, the median PFS was 4.2&#x02009;months (95% confidence interval [CI] 3.8&#x02013;4.5). The ORR was 7.5% and the CBR was 31.3%. The efficacy of chidamide was consistent in patients pretreated with CDK4/6 inhibitors and patients treated with different endocrine combinations. Multivariate analysis indicated that patients who had liver metastases (adjusted HR&#x02009;=&#x02009;1.66, 95% CI 1.14&#x02013;2.43, adjusted <em>p</em>&#x02009;=&#x02009;0.008) or &#x02265;3 prior lines of treatment (adjusted HR&#x02009;=&#x02009;1.80, 95% CI 1.17&#x02013;2.77, adjusted <em>p</em>&#x02009;=&#x02009;0.008) had significantly worse PFS. The most common AEs with chidamide were thrombocytopenia, leucopenia, neutropenia, and anemia.</p></div><div id="cam46762-sec-0004" class="sec sec-last"><h3 id="cam46762-sec-0004title">Conclusion</h3><p class="p p-first-last">This study provided real&#x02010;world data for the use of chidamide in patients with HoR&#x02010;positive and HER2&#x02010;negative MBC. Our data endorsed the use of chidamide in patients pretreated with CDK4/6 inhibitors and patients treated with different endocrine combinations.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">chidamide, endocrine therapy, hormone receptor&#x02010;positive, metastatic breast cancer, real&#x02010;world data</span></div></div><div id="cam46762-sec-0005" class="tsec sec"><h2 class="head no_bottom_margin" id="cam46762-sec-0005title">1. INTRODUCTION</h2><p class="p p-first">Breast cancer has become the most frequently diagnosed malignancy worldwide,<sup><a href="#cam46762-bib-0001" rid="cam46762-bib-0001" class=" bibr popnode">
1
</a></sup> and hormone receptor (HoR)&#x02010;positive breast cancer represents the majority of breast cancer patients.<sup><a href="#cam46762-bib-0002" rid="cam46762-bib-0002" class=" bibr popnode">
2
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0003" rid="cam46762-bib-0003" class=" bibr popnode">
3
</a></sup> Endocrine therapy suppresses tumor growth and development through blocking estrogen/estrogen receptor (ER) axis. It greatly reduces cancer recurrence and prolongs patients' survival and is the mainstay of HoR&#x02010;positive breast cancer treatment. However, the efficacy of endocrine therapy is considerably challenged by intrinsic or acquired endocrine resistance that can occur in a large subset of HoR positive patients.<sup><a href="#cam46762-bib-0004" rid="cam46762-bib-0004" class=" bibr popnode">
4
</a></sup> Even though the advent of cyclin dependent kinase (CDK) 4/6 inhibitors (e.g., palbociclib, abemaciclib, ribociclib, and dalpiciclib) has marked a new era of HoR&#x02010;positive breast cancer treatment, the addition of CDK4/6 inhibitors can only abrogate part of endocrine resistance. Treatment choices after disease progression on CDK4/6 inhibitors remain limited. Therefore, it is significant to explore the mechanisms and develop more effective strategies to overcome endocrine resistance in HoR&#x02010;positive patients, especially those with recurrent or metastatic breast cancer (MBC).</p><p>Chidamide (also known as tucidinostat) is an oral type, selective histone deacetylase (HDAC) inhibitor, which acts through epigenetic regulations to induce cell cycle arrest and apoptosis in tumor cells. Epigenetic reprogramming impacts ER downstream transcription factors, triggers parallel pathways independent of estrogen/ER that promote tumor growth, and is implicated with endocrine resistance. Preclinical studies have shown the potential efficacy of HDAC inhibitors to enhance the sensitivity of AIs and suppress aberrantly activated growth factor signaling pathways in breast cancer.<sup><a href="#cam46762-bib-0005" rid="cam46762-bib-0005" class=" bibr popnode">
5
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0006" rid="cam46762-bib-0006" class=" bibr popnode">
6
</a></sup> Chidamide has also been reported to enhance antibody&#x02010;dependent cell&#x02010;mediated cytotoxicity and cytotoxic T cell&#x02010;mediated anti&#x02010;tumor immunity,<sup><a href="#cam46762-bib-0007" rid="cam46762-bib-0007" class=" bibr popnode">
7
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0008" rid="cam46762-bib-0008" class=" bibr popnode">
8
</a></sup> and reverse epithelial&#x02010;mesenchymal phenotype transformation (EMT) of tumor cells.<sup><a href="#cam46762-bib-0009" rid="cam46762-bib-0009" class=" bibr popnode">
9
</a></sup> In an exploratory phase II trial, chidamide plus exemestane was adequately tolerated and effective in patients with HoR&#x02010;positive MBC.<sup><a href="#cam46762-bib-0010" rid="cam46762-bib-0010" class=" bibr popnode">
10
</a></sup> A phase III randomized controlled trial (ACE study) proved that chidamide combined with exemestane improved progression&#x02010;free survival (PFS) in patients with advanced, HoR&#x02010;positive breast cancer who progressed after previous endocrine therapy compared with placebo plus exemestane.<sup><a href="#cam46762-bib-0011" rid="cam46762-bib-0011" class=" bibr popnode">
11
</a></sup> Based on the evidence from ACE trial, chidamide was approved for postmenopausal patients with HoR&#x02010;positive, human epidermal growth factor receptor 2 (HER2)&#x02010;negative advanced or MBC who relapsed or progressed on endocrine therapy.</p><p class="p p-last">Further investigations on its efficacy and safety in the real&#x02010;world clinical practice is still warranted. In the ACE trial, only very few patients received CDK4/6 inhibitors since none of these agents were approved in China during the recruitment of the ACE study. However, in real world, a large proportion of metastatic patients had the treatment with CDK4/6 inhibitors in the frontier lines since it has been set as new standard. Therefore, the benefit of chidamide in patients who progressed on CDK4/6 inhibitors needs further investigation. Additionally, over three quarters of the patients treated with chidamide received &#x0003c;2 lines of previous treatments for MBC in the trial, while patients treated with chidamide in real&#x02010;world scenario tend to have more prior lines of therapy. Furthermore, more data on the combination of chidamide with other anti&#x02010;estrogen agents are needed since many patients have been pretreated with exemestane in daily practice. In this multicenter study, we aimed to investigate the real&#x02010;world effectiveness, toxicity, and treatment patterns of chidamide in patients with HoR&#x02010;positive MBC and find potential clinicopathological factors for efficacy prediction.</p></div><div id="cam46762-sec-0006" class="tsec sec"><h2 class="head no_bottom_margin" id="cam46762-sec-0006title">2. PATIENTS AND METHODS</h2><div id="cam46762-sec-0007" class="sec sec-first"><h3 id="cam46762-sec-0007title">2.1. Study population and treatment</h3><p class="p p-first">This multicenter cohort study enrolled consecutive breast cancer patients treated with chidamide from January 2020 to August 2021 across 11 institutions, including Fudan University Shanghai Cancer Center, Zhongshan hospital, Huashan hospital, Huadong hospital, Shanghai East Hospital, Shanghai Tenth People's Hospital, Changhai Hospital, Shanghai General Hospital, Renji Hospital, Ruijin Hospital, and Huangpu Branch of Shanghai Ninth People's Hospital. All data were retrospectively collected through the institutions' electronic medical record. Eligible patients were pre&#x02010; and postmenopausal women with clinically or histologically confirmed ER&#x02010;positive, HER2&#x02010;negative breast cancer, who had at least one recurrent/metastatic lesion; and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients with multiple primary malignancies or unavailable baseline characteristics were excluded.</p><p class="p p-last">Patients received 30&#x02009;mg chidamide orally twice a week for four consecutive weeks in a 4&#x02010;week&#x02009;cycle, combined with exemestane 25&#x02009;mg orally daily/anastrozole 1&#x02009;mg orally daily/letrozole 2.5&#x02009;mg orally daily/tamoxifen 10&#x02009;mg orally twice daily/toremifene 60&#x02009;mg orally daily/fulvestrant 500&#x02009;mg intramuscularly once a month. Each premenopausal patient received ovarian function suppression (OFS) with concurrent endocrine therapy. Treatment was administered until disease progression, intolerable toxicity, or patient refusal.</p></div><div id="cam46762-sec-0008" class="sec"><h3 id="cam46762-sec-0008title">2.2. Outcome</h3><p class="p p-first-last">Efficacy analyses included PFS, objective response rate (ORR), and clinical benefit rate (CBR). PFS was defined as the time from treatment initiation of chidamide to disease progression or death due to any cause. ORR was defined as the proportion of patients achieved complete response (CR) or partial response (PR) as the best objective tumor response. CBR was defined as the proportion of patients who achieved CR, PR, or had stable disease (SD) for at least 24&#x02009;weeks as the best objective tumor response. Tumor assessments were performed approximately every 3&#x02009;months or when signs of disease progression were shown until treatment discontinuations. Efficacy was assessed based on regular CT and/or MRI tests according to the Response Evaluation Criteria in Solid tumors (RECIST) 1.1.<sup><a href="#cam46762-bib-0012" rid="cam46762-bib-0012" class=" bibr popnode">
12
</a></sup> Adverse events (AEs) and laboratory abnormalities were documented every regular follow&#x02010;up according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI&#x02010;CTCAEs) version 5.0.</p></div><div id="cam46762-sec-0009" class="sec sec-last"><h3 id="cam46762-sec-0009title">2.3. Statistical analyses</h3><p class="p p-first-last">Efficacy analyses and safety analyses were performed in all included patients. We calculated median PFS and plotted time&#x02010;to&#x02010;event curves using Kaplan&#x02013;Meier method, and compared the median PFS of different subgroups using log&#x02010;rank tests. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated with the Cox proportional hazards model. Univariate analyses were performed to screen the potential variables associated with PFS, including menstrual status (premenopausal vs. postmenopausal), age (&#x0003c;65 vs. &#x02265;65&#x02009;years old), ECOG status (0 vs. 1), visceral metastases (yes vs. no), lung metastases (yes vs. no), liver metastases (yes vs. no), number of metastatic organs (0&#x02013;1 vs. &#x02265;2), number of lines prior to chidamide (0&#x02013;2 vs. &#x02265;3), previous endocrine therapy for MBC (yes vs. no), sensitive to endocrine therapy (yes vs. no), previous use of CDK4/6 inhibitors (yes vs. no), previous chemotherapy for MBC (yes vs. no). Sensitivity to endocrine therapy was defined as at least 24&#x02009;months of endocrine therapy before recurrence in the adjuvant setting or a response or stabilization for at least 6&#x02009;months with endocrine therapy for advanced disease. In patients who relapsed while on adjuvant endocrine therapy or within 12&#x02009;months of completing adjuvant endocrine therapy, adjuvant endocrine therapy was considered as an additional line prior to the treatment with chidamide. Variables significant in the univariate analyses were further evaluated in the multivariate analyses. Multivariable cox proportional hazards models with forward selection were used to identify independent predictors of PFS. All <em>p</em>&#x02010;values were two&#x02010;sided and considered statistically significant when &#x0003c;0.05.</p></div></div><div id="cam46762-sec-0010" class="tsec sec"><h2 class="head no_bottom_margin" id="cam46762-sec-0010title">3. RESULTS</h2><div id="cam46762-sec-0011" class="sec sec-first"><h3 id="cam46762-sec-0011title">3.1. Patient characteristics</h3><p class="p p-first">From January 2020 to August 2021, 170 breast cancer patients treated with chidamide were assessed for eligibility and 157 patients were finally included for analysis. Reasons for exclusion have been detailed in the patient selection flow chart (Figure&#x000a0;<a href="/pmc/articles/PMC10923034/figure/cam46762-fig-0001/" target="figure" class="fig-table-link figpopup" rid-figpopup="cam46762-fig-0001" rid-ob="ob-cam46762-fig-0001" co-legend-rid="lgnd_cam46762-fig-0001"><span>1</span></a>). Clinicopathological characteristics and treatment combinations of included patients are reported in Table&#x000a0;<a href="/pmc/articles/PMC10923034/table/cam46762-tbl-0001/" target="table" class="fig-table-link figpopup" rid-figpopup="cam46762-tbl-0001" rid-ob="ob-cam46762-tbl-0001" co-legend-rid=""><span>1</span></a>. The median age of included patients was 55&#x02009;years old, and most patients (80.9%) were postmenopausal. 126 patients (80.3%) were both ER&#x02010; and PR&#x02010;positive, while 19.7% patients were PR&#x02010;negative. Most of the patients (70.1%) had visceral metastases, including lung (43.9%), brain (3.8%), and liver (43.3%). Bone involvement occurred in 70.1% of all included patients.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="cam46762-fig-0001" co-legend-rid="lgnd_cam46762-fig-0001"><a href="/pmc/articles/PMC10923034/figure/cam46762-fig-0001/" target="figure" rid-figpopup="cam46762-fig-0001" rid-ob="ob-cam46762-fig-0001"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139793794762624"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is CAM4-13-e6762-g002.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is CAM4-13-e6762-g002.jpg" src="/pmc/articles/PMC10923034/bin/CAM4-13-e6762-g002.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm139793794762624"><a target="object" rel="noopener" href="/pmc/articles/PMC10923034/figure/cam46762-fig-0001/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_cam46762-fig-0001"><div><a class="figpopup" href="/pmc/articles/PMC10923034/figure/cam46762-fig-0001/" target="figure" rid-figpopup="cam46762-fig-0001" rid-ob="ob-cam46762-fig-0001">FIGURE 1</a></div><!--caption a7--><div class="caption"><p>Flow chart of patient selection.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="cam46762-tbl-0001"><h3>TABLE 1</h3><!--caption a7--><div class="caption"><p>Baseline characteristics.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="left" valign="bottom" rowspan="1" colspan="1">Patients (<em>N</em>&#x02009;=&#x02009;157)</th><th align="left" valign="bottom" rowspan="1" colspan="1">%</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="3" valign="top" rowspan="1">Age (years)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean&#x02009;&#x000b1;&#x02009;SD</td><td align="left" valign="top" rowspan="1" colspan="1">56.67&#x02009;&#x000b1;&#x02009;10.57</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median</td><td align="left" valign="top" rowspan="1" colspan="1">55</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Range</td><td align="left" valign="top" rowspan="1" colspan="1">33&#x02013;86</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">Menstrual status</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Premenopausal</td><td align="left" valign="top" rowspan="1" colspan="1">30</td><td align="left" valign="top" rowspan="1" colspan="1">19.1%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Postmenopausal</td><td align="left" valign="top" rowspan="1" colspan="1">127</td><td align="left" valign="top" rowspan="1" colspan="1">80.9%</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">ECOG status</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">1.9%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">154</td><td align="left" valign="top" rowspan="1" colspan="1">98.1%</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">HoR status</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ER&#x02010;positive/PR&#x02010;positive</td><td align="left" valign="top" rowspan="1" colspan="1">126</td><td align="left" valign="top" rowspan="1" colspan="1">80.3%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ER&#x02010;positive/PR&#x02010;negative</td><td align="left" valign="top" rowspan="1" colspan="1">31</td><td align="left" valign="top" rowspan="1" colspan="1">19.7%</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">Metastatic site</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Visceral</td><td align="left" valign="top" rowspan="1" colspan="1">110</td><td align="left" valign="top" rowspan="1" colspan="1">70.1%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lung</td><td align="left" valign="top" rowspan="1" colspan="1">69</td><td align="left" valign="top" rowspan="1" colspan="1">43.9%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Brain</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">3.8%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Liver</td><td align="left" valign="top" rowspan="1" colspan="1">68</td><td align="left" valign="top" rowspan="1" colspan="1">43.3%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Bone</td><td align="left" valign="top" rowspan="1" colspan="1">110</td><td align="left" valign="top" rowspan="1" colspan="1">70.1%</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">Number of metastatic organs<sup>
a
</sup>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="top" rowspan="1" colspan="1">68</td><td align="left" valign="top" rowspan="1" colspan="1">43.3%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;2</td><td align="left" valign="top" rowspan="1" colspan="1">89</td><td align="left" valign="top" rowspan="1" colspan="1">56.7%</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">Number of lines prior to chidamide<sup>
b
</sup>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Range</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x02013;13</td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">1.3%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">7.0%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">33</td><td align="left" valign="top" rowspan="1" colspan="1">21.0%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">28</td><td align="left" valign="top" rowspan="1" colspan="1">17.8%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">4 and more than 4</td><td align="left" valign="top" rowspan="1" colspan="1">83</td><td align="left" valign="top" rowspan="1" colspan="1">52.9%</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">Previous endocrine therapy for metastatic disease</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">137</td><td align="left" valign="top" rowspan="1" colspan="1">87.3%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">12.7%</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">Previous use of CDK4/6 inhibitors</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">86</td><td align="left" valign="top" rowspan="1" colspan="1">54.8%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">71</td><td align="left" valign="top" rowspan="1" colspan="1">45.2%</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">Sensitive to previous endocrine therapy<sup>
c
</sup>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">110</td><td align="left" valign="top" rowspan="1" colspan="1">70.1%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">47</td><td align="left" valign="top" rowspan="1" colspan="1">29.9%</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">Previous chemotherapy</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">For neoadjuvant treatment</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">4.5%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">For adjuvant treatment</td><td align="left" valign="top" rowspan="1" colspan="1">123</td><td align="left" valign="top" rowspan="1" colspan="1">78.3%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">For metastatic settings</td><td align="left" valign="top" rowspan="1" colspan="1">95</td><td align="left" valign="top" rowspan="1" colspan="1">60.5%</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">Combination therapy</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Aromatase inhibitors</td><td align="left" valign="top" rowspan="1" colspan="1">112</td><td align="left" valign="top" rowspan="1" colspan="1">71.3%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Fulvestrant</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">8.9%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Selective estrogen receptor modulators</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">7.6%</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">12.1%</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm139793792332048"><a target="object" rel="noopener" href="/pmc/articles/PMC10923034/table/cam46762-tbl-0001/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="cam46762-note-0005"><p class="p p-first-last">Abbreviations: ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HoR, hormone receptor; PR, progesterone receptor; SD, standard deviation.</p></div><div id="cam46762-note-0002"><sup>
a
</sup>Only visceral and bone metastases were calculated.</div><div id="cam46762-note-0003"><sup>
b
</sup>In patients who relapsed while on adjuvant endocrine therapy or within 12&#x02009;months of completing adjuvant endocrine therapy, adjuvant endocrine therapy was considered as an additional line prior to the treatment with chidamide.</div><div id="cam46762-note-0004"><sup>
c
</sup>Sensitivity was defined as at least 24&#x02009;months of endocrine therapy before recurrence in the adjuvant setting or a response or stabilization for at least 6&#x02009;months with endocrine therapy for advanced disease.</div></div></div><p>The median number of lines prior to chidamide was four (ranging from 0 to 13). Only two patients received chidamide as the first&#x02010;line therapy, and 11 patients received one prior line of therapy before chidamide. A vast majority of patients (87.3%) had previous endocrine therapy and most patients (60.5%) had previous chemotherapy for metastatic disease. Over a half of patients (54.8%) received endocrine therapy combined with CDK4/6 inhibitors previously. 47 patients (29.9%) had endocrine resistance and 110 patients (70.1%) were sensitive to previous endocrine therapy. Chidamide were most commonly combined with aromatase inhibitors (AIs) (71.3%), while fulvestrant (8.9%) and selective estrogen receptor modulators (SERMs) (7.6%) were also used in some patients.</p><p class="p p-last">Up to June 10, 2022, 14 patients (8.9%) were still receiving chidamide. Patients discontinued the treatment due to the following reasons: disease progression or death (114/157, 72.6%), intolerable toxicity (25/157, 15.9%), patient refusal because of additional comorbidities (1/157, 0.6%), or loss of follow&#x02010;up (3/157, 1.9%).</p></div><div id="cam46762-sec-0012" class="sec"><h3 id="cam46762-sec-0012title">3.2. Efficacy analyses</h3><p class="p p-first">The median duration of follow&#x02010;up was 18.9&#x02009;months (interquartile range [IQR] 14.8&#x02013;23.4) at the cutoff date (June 10, 2022). In the whole cohort, the median PFS was 4.2&#x02009;months (95% CI 3.8&#x02013;4.5) (Figure&#x000a0;<a href="/pmc/articles/PMC10923034/figure/cam46762-fig-0002/" target="figure" class="fig-table-link figpopup" rid-figpopup="cam46762-fig-0002" rid-ob="ob-cam46762-fig-0002" co-legend-rid="lgnd_cam46762-fig-0002"><span>2A</span></a> and Table&#x000a0;<a href="/pmc/articles/PMC10923034/table/cam46762-tbl-0002/" target="table" class="fig-table-link figpopup" rid-figpopup="cam46762-tbl-0002" rid-ob="ob-cam46762-tbl-0002" co-legend-rid=""><span>2</span></a>). In evaluable patients, the ORR was 7.5% (10/134) and the CBR was 31.3% (42/134) (Table&#x000a0;<a href="/pmc/articles/PMC10923034/table/cam46762-tbl-0002/" target="table" class="fig-table-link figpopup" rid-figpopup="cam46762-tbl-0002" rid-ob="ob-cam46762-tbl-0002" co-legend-rid=""><span>2</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="cam46762-fig-0002" co-legend-rid="lgnd_cam46762-fig-0002"><a href="/pmc/articles/PMC10923034/figure/cam46762-fig-0002/" target="figure" rid-figpopup="cam46762-fig-0002" rid-ob="ob-cam46762-fig-0002"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139793795820960"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is CAM4-13-e6762-g001.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is CAM4-13-e6762-g001.jpg" src="/pmc/articles/PMC10923034/bin/CAM4-13-e6762-g001.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm139793795820960"><a target="object" rel="noopener" href="/pmc/articles/PMC10923034/figure/cam46762-fig-0002/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_cam46762-fig-0002"><div><a class="figpopup" href="/pmc/articles/PMC10923034/figure/cam46762-fig-0002/" target="figure" rid-figpopup="cam46762-fig-0002" rid-ob="ob-cam46762-fig-0002">FIGURE 2</a></div><!--caption a7--><div class="caption"><p>Kaplan&#x02013;Meier plots for PFS in patients treated with chidamide. (A) PFS in all included patients; (B) PFS in patients stratified by line of treatment with chidamide; (C) PFS in patients stratified by previous use of CDK4/6i; (D) PFS in patients stratified by combination therapies. CDK4/6i, cyclin dependent kinase 4/6 inhibitors; PFS, progression&#x02010;free survival.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="cam46762-tbl-0002"><h3>TABLE 2</h3><!--caption a7--><div class="caption"><p>Efficacy analysis.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"></th><th align="left" valign="bottom" rowspan="1" colspan="1">Number of patients (<em>N</em>&#x02009;=&#x02009;157)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="2" valign="top" rowspan="1">Progression&#x02010;free survival</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Disease progression or death</td><td align="left" valign="top" rowspan="1" colspan="1">114 (72.6%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Kaplan&#x02013;Meier median, months</td><td align="left" valign="top" rowspan="1" colspan="1">4.2 (3.8&#x02013;4.5)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Best overall response</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Complete response</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Partial response</td><td align="left" valign="top" rowspan="1" colspan="1">10 (6.4%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Stable disease</td><td align="left" valign="top" rowspan="1" colspan="1">49 (31.2%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Progressive disease</td><td align="left" valign="top" rowspan="1" colspan="1">75 (47.8%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Not evaluable or unknown</td><td align="left" valign="top" rowspan="1" colspan="1">23 (14.6%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Objective response<sup>
a
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">10 (7.5%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Clinical benefit<sup>
a
</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">42 (31.3%)</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm139793803907504"><a target="object" rel="noopener" href="/pmc/articles/PMC10923034/table/cam46762-tbl-0002/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="cam46762-note-0006"><sup>
a
</sup>In evaluable patients.</div><div id="cam46762-note-0007"><p class="p p-first-last">
<em>Note</em>: Data are <em>n</em> (%), median (95% CI), or <em>n</em>/<em>N</em> (%).</p></div></div></div><p>In patients treated with chidamide as the 1st&#x02010;/2nd&#x02010;line therapy, the median PFS was 9.8&#x02009;months (95% CI 1.7&#x02013;18.0). The median PFS was 5.9&#x02009;months (95% CI 3.4&#x02013;8.5) in patients received third&#x02010;line chidamide and was 3.9&#x02009;months (95% CI 3.4&#x02013;4.4) in patients who received chidamide in the fourth&#x02010;line or beyond settings (Figure&#x000a0;<a href="/pmc/articles/PMC10923034/figure/cam46762-fig-0002/" target="figure" class="fig-table-link figpopup" rid-figpopup="cam46762-fig-0002" rid-ob="ob-cam46762-fig-0002" co-legend-rid="lgnd_cam46762-fig-0002"><span>2B</span></a>). The ORR was 15.4% (6/39) and the CBR was 46.2% (18/39) in evaluable patients treated with chidamide as the first&#x02212;/second&#x02212;/third&#x02010;line therapy.</p><p>Patients who had prior use of CDK4/6 inhibitors had a median PFS of 3.7&#x02009;months (95% CI 2.8&#x02013;4.6) and those who had not been treated with CDK4/6 inhibitors had a median PFS of 4.4&#x02009;months (95% CI 4.0&#x02013;4.7). The prior use of CDK4/6 inhibitors did not significantly affect PFS in patients treated with chidamide (<em>p</em>&#x02009;=&#x02009;0.115) (Figure&#x000a0;<a href="/pmc/articles/PMC10923034/figure/cam46762-fig-0002/" target="figure" class="fig-table-link figpopup" rid-figpopup="cam46762-fig-0002" rid-ob="ob-cam46762-fig-0002" co-legend-rid="lgnd_cam46762-fig-0002"><span>2C</span></a>). The median PFS of patients treated with chidamide combined with AIs (4.2&#x02009;months, 95% CI 3.8&#x02013;4.6) was comparable to those who combined with non&#x02010;AIs (3.7&#x02009;months, 95% CI 1.7&#x02013;5.7, <em>p</em>&#x02009;=&#x02009;0.377) (Figure&#x000a0;<a href="/pmc/articles/PMC10923034/figure/cam46762-fig-0002/" target="figure" class="fig-table-link figpopup" rid-figpopup="cam46762-fig-0002" rid-ob="ob-cam46762-fig-0002" co-legend-rid="lgnd_cam46762-fig-0002"><span>2D</span></a>).</p><p class="p">Univariate Cox regression analyses demonstrated that liver metastases (<em>p</em>&#x02009;=&#x02009;0.004), number of lines prior to chidamide (<em>p</em>&#x02009;=&#x02009;0.004), previous endocrine therapy for MBC (<em>p</em>&#x02009;=&#x02009;0.008), and previous chemotherapy for MBC (<em>p</em>&#x02009;=&#x02009;0.016) were significantly correlated with PFS in patients treated with chidamide. The above variables significant in the univariate analyses were further evaluated in the multivariate analyses. We used multivariable cox proportional hazards model with forward selection to identify independent predictors of PFS. The variables included in the final multivariable cox proportional hazards model were liver metastases and lines of therapy. Multivariate analysis indicated that patients who had liver metastases (adjusted HR&#x02009;=&#x02009;1.66, 95% CI 1.14&#x02013;2.43, adjusted <em>p</em>&#x02009;=&#x02009;0.008) or &#x02265;3 prior lines of treatment (adjusted HR&#x02009;=&#x02009;1.80, 95% CI 1.17&#x02013;2.77, adjusted <em>p</em>&#x02009;=&#x02009;0.008) had significantly worse PFS (Table&#x000a0;<a href="/pmc/articles/PMC10923034/table/cam46762-tbl-0003/" target="table" class="fig-table-link figpopup" rid-figpopup="cam46762-tbl-0003" rid-ob="ob-cam46762-tbl-0003" co-legend-rid=""><span>3</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="cam46762-tbl-0003"><h3>TABLE 3</h3><!--caption a7--><div class="caption"><p>Univariate and multivariate analyses of progression&#x02010;free survival in patients treated with chidamide.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Characteristics</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Univariate analysis</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Multivariate analysis</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">HR</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<em>p</em>&#x02010;value</th><th align="left" valign="bottom" rowspan="1" colspan="1">HR</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<em>p</em>&#x02010;value</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="7" valign="top" rowspan="1">Menstrual status</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Premenopausal</td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Postmenopausal</td><td align="left" valign="top" rowspan="1" colspan="1">1.44</td><td align="left" valign="top" rowspan="1" colspan="1">0.90&#x02013;2.31</td><td align="left" valign="top" rowspan="1" colspan="1">0.126</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Age</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003c;65</td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;65</td><td align="left" valign="top" rowspan="1" colspan="1">0.86</td><td align="left" valign="top" rowspan="1" colspan="1">0.55&#x02013;1.34</td><td align="left" valign="top" rowspan="1" colspan="1">0.493</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">ECOG status</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.72</td><td align="left" valign="top" rowspan="1" colspan="1">0.23&#x02013;2.26</td><td align="left" valign="top" rowspan="1" colspan="1">0.567</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Progesterone&#x02010;receptor status</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Positive</td><td align="left" valign="top" rowspan="1" colspan="1">0.85</td><td align="left" valign="top" rowspan="1" colspan="1">0.54&#x02013;1.32</td><td align="left" valign="top" rowspan="1" colspan="1">0.468</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Visceral metastases</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">1.38</td><td align="left" valign="top" rowspan="1" colspan="1">0.92&#x02013;2.08</td><td align="left" valign="top" rowspan="1" colspan="1">0.119</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Lung metastases</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">0.98</td><td align="left" valign="top" rowspan="1" colspan="1">0.67&#x02013;1.42</td><td align="left" valign="top" rowspan="1" colspan="1">0.910</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Liver metastases</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">1.74</td><td align="left" valign="top" rowspan="1" colspan="1">1.19&#x02013;2.53</td><td align="left" valign="top" rowspan="1" colspan="1">
<strong>0.004**</strong>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.66</td><td align="left" valign="top" rowspan="1" colspan="1">1.14&#x02013;2.43</td><td align="left" valign="top" rowspan="1" colspan="1">
<strong>0.008**</strong>
</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Number of metastatic organs<sup>
a
</sup>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;2</td><td align="left" valign="top" rowspan="1" colspan="1">1.38</td><td align="left" valign="top" rowspan="1" colspan="1">0.95&#x02013;2.01</td><td align="left" valign="top" rowspan="1" colspan="1">0.090</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Number of lines prior to chidamide<sup>
b
</sup>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">0&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;3</td><td align="left" valign="top" rowspan="1" colspan="1">1.87</td><td align="left" valign="top" rowspan="1" colspan="1">1.22&#x02013;2.88</td><td align="left" valign="top" rowspan="1" colspan="1">
<strong>0.004**</strong>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.80</td><td align="left" valign="top" rowspan="1" colspan="1">1.17&#x02013;2.77</td><td align="left" valign="top" rowspan="1" colspan="1">
<strong>0.008**</strong>
</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Previous endocrine therapy for metastatic disease</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">2.33</td><td align="left" valign="top" rowspan="1" colspan="1">1.24&#x02013;4.35</td><td align="left" valign="top" rowspan="1" colspan="1">
<strong>0.008**</strong>
</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Sensitive to previous endocrine therapy<sup>
c
</sup>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">1.33</td><td align="left" valign="top" rowspan="1" colspan="1">0.89&#x02013;1.98</td><td align="left" valign="top" rowspan="1" colspan="1">0.159</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Previous use of CDK4/6 inhibitors</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">1.35</td><td align="left" valign="top" rowspan="1" colspan="1">0.93&#x02013;1.96</td><td align="left" valign="top" rowspan="1" colspan="1">0.117</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Previous chemotherapy for metastatic disease</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Reference</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">1.62</td><td align="left" valign="top" rowspan="1" colspan="1">1.09&#x02013;2.39</td><td align="left" valign="top" rowspan="1" colspan="1">
<strong>0.016*</strong>
</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm139793795297664"><a target="object" rel="noopener" href="/pmc/articles/PMC10923034/table/cam46762-tbl-0003/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="cam46762-note-0011"><p class="p p-first-last">Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio.</p></div><div id="cam46762-note-0008"><sup>
a
</sup>Only visceral and bone metastases were calculated.</div><div id="cam46762-note-0009"><sup>
b
</sup>In patients who relapsed while on adjuvant endocrine therapy or within 12&#x02009;months of completing adjuvant endocrine therapy, adjuvant endocrine therapy was considered as an additional line prior to the treatment with chidamide.</div><div id="cam46762-note-0010"><sup>
c
</sup>Sensitivity was defined as at least 24&#x02009;months of endocrine therapy before recurrence in the adjuvant setting or a response or stabilization for at least 6&#x02009;months with endocrine therapy for advanced disease.</div><div id="cam46762-note-0110"><p class="p p-first-last">
<em>p</em>&#x02010;values were considered statistically significant when &#x0003c;0.05 (in bold). *<em>p</em> &#x0003c;0.05; **<em>p</em> &#x0003c;0.01.</p></div></div></div></div><div id="cam46762-sec-0013" class="sec"><h3 id="cam46762-sec-0013title">3.3. Treatment choices of next&#x02010;line therapy</h3><p class="p p-first">Among the 66 patients with known next&#x02010;line therapy after chidamide treatment, 47 patients switched to chemotherapy as the post first&#x02010;line treatment, and 15 patients received subsequent endocrine therapy. A patient with HER2&#x02010;low breast cancer who progressed on chidamide was enrolled in the clinical trial and treated with trastuzumab deruxtecan (T&#x02010;DXd). Other post first&#x02010;line treatments included PI3K inhibitors and programmed cell death protein&#x02010;1 (PD&#x02010;1) inhibitors (Figure&#x000a0;<a href="/pmc/articles/PMC10923034/figure/cam46762-fig-0003/" target="figure" class="fig-table-link figpopup" rid-figpopup="cam46762-fig-0003" rid-ob="ob-cam46762-fig-0003" co-legend-rid="lgnd_cam46762-fig-0003"><span>3A</span></a>). In the 17 patients who received endocrine therapy combined with CDK4/6 inhibitors post chidamide, most patients used CDK4/6 inhibitors in the post first&#x02010;line settings (Figure&#x000a0;<a href="/pmc/articles/PMC10923034/figure/cam46762-fig-0003/" target="figure" class="fig-table-link figpopup" rid-figpopup="cam46762-fig-0003" rid-ob="ob-cam46762-fig-0003" co-legend-rid="lgnd_cam46762-fig-0003"><span>3B</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="cam46762-fig-0003" co-legend-rid="lgnd_cam46762-fig-0003"><a href="/pmc/articles/PMC10923034/figure/cam46762-fig-0003/" target="figure" rid-figpopup="cam46762-fig-0003" rid-ob="ob-cam46762-fig-0003"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139793778868304"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is CAM4-13-e6762-g003.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is CAM4-13-e6762-g003.jpg" src="/pmc/articles/PMC10923034/bin/CAM4-13-e6762-g003.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm139793778868304"><a target="object" rel="noopener" href="/pmc/articles/PMC10923034/figure/cam46762-fig-0003/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_cam46762-fig-0003"><div><a class="figpopup" href="/pmc/articles/PMC10923034/figure/cam46762-fig-0003/" target="figure" rid-figpopup="cam46762-fig-0003" rid-ob="ob-cam46762-fig-0003">FIGURE 3</a></div><!--caption a7--><div class="caption"><p>Treatment choices after chidamide treatment. (A) Next&#x02010;line treatment after chidamide treatment. (B) The proportion of patients treated with post&#x02010;first/second/third/fourth&#x02010;line CDK4/6 inhibitors. PD&#x02010;1, programmed cell death protein&#x02010;1.</p></div></div></div></div><div id="cam46762-sec-0014" class="sec sec-last"><h3 id="cam46762-sec-0014title">3.4. Safety</h3><p class="p p-first">The most common AEs with chidamide were thrombocytopenia (35.0%), leucopenia (26.8%), neutropenia (23.6%), and anemia (14.0%). Nausea (13.4%) and vomiting (10.2%) were also non&#x02010;hematological toxicities commonly seen in patients. The most common Grade 3/4 AEs were thrombocytopenia (10.8%) and neutropenia (6.4%). The hematological AEs were mostly manageable, and were reversible after the discontinuation of chidamide (Table&#x000a0;<a href="/pmc/articles/PMC10923034/table/cam46762-tbl-0004/" target="table" class="fig-table-link figpopup" rid-figpopup="cam46762-tbl-0004" rid-ob="ob-cam46762-tbl-0004" co-legend-rid=""><span>4</span></a>). No cases of febrile neutropenia were reported.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="cam46762-tbl-0004"><h3>TABLE 4</h3><!--caption a7--><div class="caption"><p>Adverse events.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Adverse events</th><th align="left" valign="bottom" rowspan="1" colspan="1">Grade 1</th><th align="left" valign="bottom" rowspan="1" colspan="1">Grade 2</th><th align="left" valign="bottom" rowspan="1" colspan="1">Grade 3</th><th align="left" valign="bottom" rowspan="1" colspan="1">Grade 4</th><th align="left" valign="bottom" rowspan="1" colspan="1">All grade</th><th align="left" valign="bottom" rowspan="1" colspan="1">(%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Grade 3/4</th><th align="left" valign="bottom" rowspan="1" colspan="1">(%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Leucopenia</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">42</td><td align="left" valign="top" rowspan="1" colspan="1">26.8%</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">5.1%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neutropenia</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">37</td><td align="left" valign="top" rowspan="1" colspan="1">23.6%</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">6.4%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anemia</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">14.0%</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">3.8%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thrombocytopenia</td><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">55</td><td align="left" valign="top" rowspan="1" colspan="1">35.0%</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">10.8%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Increased aspartate/alanine aminotransferase</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">9.6%</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">1.9%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Increase blood creatine phosphokinase</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">1.3%</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.6%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nausea</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="left" valign="top" rowspan="1" colspan="1">13.4%</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">2.5%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vomiting</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">10.2%</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">1.3%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diarrhea</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">7.6%</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.6%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Abdominal pain/abdominal distension</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">2.5%</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0.0%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anorexia</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">6.4%</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.6%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">8.3%</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">1.3%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pedal edema</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">3.2%</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">1.3%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Interstitial lung Disease</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">3.2%</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.6%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pain</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">6.4%</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0.6%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thromboembolic Events</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0.0%</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0.0%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dizziness</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0.0%</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0.0%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Palpitations</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0.0%</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0.0%</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm139793778862352"><a target="object" rel="noopener" href="/pmc/articles/PMC10923034/table/cam46762-tbl-0004/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="cam46762-note-0012"><p class="p p-first-last">
<em>Note</em>: For any listed adverse event, each patient was counted according to the worst severity grade.</p></div></div></div></div></div><div id="cam46762-sec-0015" class="tsec sec"><h2 class="head no_bottom_margin" id="cam46762-sec-0015title">4. DISCUSSION</h2><p class="p p-first">In this multicenter, retrospective study, patients with HoR&#x02010;positive, HER2&#x02010;negative MBC receiving chidamide demonstrated a median PFS of 4.2&#x02009;months. The ORR was 7.5% and the CBR was 31.3% in evaluable patients. The median PFS was 9.8&#x02009;months in patients treated with chidamide as the first&#x02212;/second&#x02010;line therapy and was 5.9&#x02009;months in patients received third&#x02010;line chidamide. The ORR was 15.4% and the CBR was 46.2% in patients treated with chidamide as the first&#x02212;/second&#x02212;/third&#x02010;line therapy. The toxicity of chidamide was generally tolerable. The most frequently reported AEs were hematological toxicities, including thrombocytopenia, leucopenia, neutropenia, and anemia.</p><p>In the ACE study, the median PFS was 7.4&#x02009;months (95% CI 5.5&#x02013;9.2) in the chidamide group. The ORR was 18% and the CBR was 47% in patients treated chidamide in the clinical trial. The numerical difference in the response rate can be partly explained by the difference in treatment population. The ORR and CBR in the clinical trial were similar to that in patients treated with first&#x02212;/second&#x02212;/third&#x02010;line chidamide in this retrospective study. In the real&#x02010;world clinical practice, chidamide tend to be used in more heavily pretreated patients. The median number of lines prior to chidamide was four and the proportion of patients treated with previous 0&#x02013;1 lines of therapy was 8.3% in this study. In contrast, in the ACE trial, over quarters of chidamide group received 0&#x02013;1 lines of previous treatment for MBC and only 3% patients had three lines of previous therapy before chidamide in the metastatic settings. In addition, a higher proportion of patients in this study had previous chemotherapy and endocrine therapy for metastatic disease in this study (60.5% and 87.3%, respectively) compared to that in the clinical trial (30.0% and 47.1%, respectively). The proportion of patients with visceral disease was also higher than that in the trial. This study demonstrated antitumor effectiveness of chidamide even used in patients with higher tumor burden or as later lines of therapy.</p><p>This study provided evidence for scenarios that have not been adequately investigated in previous trials but commonly seen in clinical practice. Our data endorsed the use of chidamide in patients pretreated with CDK4/6 inhibitors. Based on the satisfactory efficacy of palbociclib,<sup><a href="#cam46762-bib-0013" rid="cam46762-bib-0013" class=" bibr popnode">
13
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0014" rid="cam46762-bib-0014" class=" bibr popnode">
14
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0015" rid="cam46762-bib-0015" class=" bibr popnode">
15
</a></sup> ribociclib,<sup><a href="#cam46762-bib-0016" rid="cam46762-bib-0016" class=" bibr popnode">
16
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0017" rid="cam46762-bib-0017" class=" bibr popnode">
17
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0018" rid="cam46762-bib-0018" class=" bibr popnode">
18
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0019" rid="cam46762-bib-0019" class=" bibr popnode">
19
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0020" rid="cam46762-bib-0020" class=" bibr popnode">
20
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0021" rid="cam46762-bib-0021" class=" bibr popnode">
21
</a></sup> abemaciclib,<sup><a href="#cam46762-bib-0022" rid="cam46762-bib-0022" class=" bibr popnode">
22
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0023" rid="cam46762-bib-0023" class=" bibr popnode">
23
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0024" rid="cam46762-bib-0024" class=" bibr popnode">
24
</a></sup> and dalpiciclib,<sup><a href="#cam46762-bib-0025" rid="cam46762-bib-0025" class=" bibr popnode">
25
</a></sup> CDK4/6 inhibitors combined endocrine therapy has been recommended as the first&#x02010;line treatment for patients with HoR&#x02010;positive, HER2&#x02010;negative MBC after progression on single&#x02010;agent endocrine therapy. Consequently, a large proportion of patients have used CDK4/6 inhibitors in the metastatic settings prior to chidamide in this study. Another multicenter study indicated that chidamide plus exemestane was one of the most frequently used endocrine therapy regimens in HoR&#x02010;positive, HER2&#x02010;negative MBC after progression on CDK4/6 inhibitors.<sup><a href="#cam46762-bib-0026" rid="cam46762-bib-0026" class=" bibr popnode">
26
</a></sup> The above evidence represents the real&#x02010;world treatment pattern for HoR&#x02010;positive, HER2&#x02010;negative MBC. Meanwhile, only very few patients had been previously treated with CDK4/6 inhibitors since none of these agents were approved in China during the recruitment of the ACE clinical trial. The real&#x02010;world efficacy data for this subpopulation in our study supplemented the previous findings. Univariate Cox regression analysis proved that the efficacy of chidamide was not affected by prior use of CDK4/6 inhibitors, lending support to the use of chidamide as a reasonable choice for those who progressed on treatment with CDK4/6 inhibitors.</p><p>Chidamide was approved in China for postmenopausal patients with HoR&#x02010;positive MBC, combined with AIs. Most patients in this study used chidamide plus AIs, while a small proportion of patients received fulvestrant or SERMs as combination regimens. Our data did not show significant difference in PFS between combinational AIs and non&#x02010;AIs when treated with chidamide. This finding indicated that those who previously progressed on AIs can also choose non&#x02010;AIs as combinational therapy without affecting efficacy. In premenopausal patients, this study proved that the efficacy of chidamide was comparable to that in the postmenopausal with simultaneous OFS.</p><p>Liver metastases (<em>p</em>&#x02009;=&#x02009;0.004), number of lines prior to chidamide (<em>p</em>&#x02009;=&#x02009;0.004), previous endocrine therapy for MBC (<em>p</em>&#x02009;=&#x02009;0.008), and previous chemotherapy for MBC (<em>p</em>&#x02009;=&#x02009;0.016) were found to be significantly associated with PFS in univariate analyses, while only liver metastases and prior lines of chidamide were identified as the independent predictors in multivariate analysis. Patients who had liver metastases (adjusted HR&#x02009;=&#x02009;1.66, 95% CI 1.14&#x02013;2.43, adjusted <em>p</em>&#x02009;=&#x02009;0.008) or &#x02265;3 prior lines of treatment (adjusted HR&#x02009;=&#x02009;1.80, 95% CI 1.17&#x02013;2.77, adjusted <em>p</em>&#x02009;=&#x02009;0.008) had significantly worse PFS. This finding may help in patient selection and treatment planning. In addition, our analyses suggested that chidamide can be considered in fronter lines of therapy in suitable metastatic cases to achieve better clinical outcomes. Univariate analyses also indicated that chidamide was equally effective in patients with endocrine resistance. In daily practice, chemotherapy is sometimes preferred over endocrine therapy even as initial palliative treatment for MBC, especially for patients who are intrinsically resistant to endocrine therapy, or those who have life&#x02010;threatening visceral metastases.<sup><a href="#cam46762-bib-0027" rid="cam46762-bib-0027" class=" bibr popnode">
27
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0028" rid="cam46762-bib-0028" class=" bibr popnode">
28
</a></sup> This study suggested that chidamide combined with endocrine therapy was a reasonable choice for these patients who were stable after the completion of chemotherapy.</p><p>Hematological toxicity and gastrointestinal toxicity were the most commonly observed AEs in this study, which was consistent with the toxicity profile of chidamide and other HDAC inhibitors in previous studies.<sup><a href="#cam46762-bib-0029" rid="cam46762-bib-0029" class=" bibr popnode">
29
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0030" rid="cam46762-bib-0030" class=" bibr popnode">
30
</a></sup><sup>, </sup><sup><a href="#cam46762-bib-0031" rid="cam46762-bib-0031" class=" bibr popnode">
31
</a></sup> The hematological AEs were generally manageable and reversible. Rare AEs that have not been discussed in the previous trials included interstitial lung disease, thromboembolic events, and palpitations. The frequency of AE&#x02010;related drug discontinuation was 17.8% in this study, highlighting that more efforts should be put into AE management during the whole treatment.</p><p class="p p-last">This study had some limitations. Due to the retrospective study design, recall bias was inevitable and the frequency of AEs may be underestimated. Some minor discomfort and asymptomatic laboratory abnormalities were difficult to track. In addition, due to the relatively short period of follow&#x02010;up, data of overall survival (OS) was not calculated in this study. Although this study proved that prior use of CDK4/6 inhibitors will not affect the efficacy of chidamide, OS data are needed for physicians to optimize the sequence of different strategies in patients progressed on previous endocrine therapies. More prospective studies are needed to address this issue and overcome the challenge of endocrine resistance for patients with luminal breast cancer.</p></div><div id="cam46762-sec-0016" class="tsec sec"><h2 class="head no_bottom_margin" id="cam46762-sec-0016title">5. CONCLUSION</h2><p class="p p-first-last">This study provided real&#x02010;world data for the use of chidamide in patients with HoR&#x02010;positive, HER2&#x02010;negative MBC. The efficacy of chidamide was consistent in patients pretreated with CDK4/6 inhibitors and patients treated with different endocrine combinations. Multivariate analysis indicated that patients who had liver metastases (adjusted HR&#x02009;=&#x02009;1.66, 95% CI 1.14&#x02013;2.43, adjusted <em>p</em>&#x02009;=&#x02009;0.008) or &#x02265;3 prior lines of treatment (adjusted HR&#x02009;=&#x02009;1.80, 95% CI 1.17&#x02013;2.77, adjusted <em>p</em>&#x02009;=&#x02009;0.008) had significantly worse PFS. Further prospective investigations on chidamide with large sample size are warranted in the future.</p></div><div id="cam46762-sec-0023" class="tsec sec"><h2 class="head no_bottom_margin" id="cam46762-sec-0023title">AUTHOR CONTRIBUTIONS</h2><p class="p p-first-last">
<strong>Doudou Li:</strong> Data curation (equal); funding acquisition (equal); investigation (equal); resources (equal); writing &#x02013; original draft (supporting); writing &#x02013; review and editing (lead). <strong>Yizi Jin:</strong> Data curation (equal); formal analysis (lead); investigation (equal); visualization (lead); writing &#x02013; original draft (lead). <strong>Mingxi Lin:</strong> Validation (lead); writing &#x02013; review and editing (supporting). <strong>Cheng Zeng:</strong> Validation (supporting); writing &#x02013; review and editing (supporting). <strong>Qing Guo:</strong> Validation (supporting); writing &#x02013; review and editing (supporting). <strong>Yanfei Liu:</strong> Conceptualization (equal); project administration (equal); supervision (equal). <strong>Jian Zhang:</strong> Conceptualization (equal); funding acquisition (equal); project administration (equal); resources (equal); supervision (equal).</p></div><div id="cam46762-sec-0017" class="tsec sec"><h2 class="head no_bottom_margin" id="cam46762-sec-0017title">FUNDING INFORMATION</h2><p class="p p-first-last">This study was supported by National Natural Science Foundation of China (grant no. 82072915, 82373359); Project of Shanghai Municipal Health Commission (grant no. 202140397); CSCO&#x02010;ROCHE Cancer Research Fund 2019 (grant no. Y&#x02010;2019Roche&#x02010;171); and Chinese Young Breast Experts Research project (grant no. CYBER&#x02010;2021&#x02010;001); Beijing Science and Technology Innovation Medical Development Foundation Key Project (grant no. KC2022&#x02010;ZZ&#x02010;0091&#x02010;6); and Shanghai Youth Technological Talent Program&#x02014;Yangfan Program (grant no. 21YF1408200).</p></div><div id="cam46762-sec-0018" class="tsec sec"><h2 class="head no_bottom_margin" id="cam46762-sec-0018title">CONFLICT OF INTEREST STATEMENT</h2><p class="p p-first-last">The authors declare that there is no conflict of interest.</p></div><div id="cam46762-sec-0021" class="tsec sec"><h2 class="head no_bottom_margin" id="cam46762-sec-0021title">ETHICS STATEMENT</h2><p class="p p-first-last">This study was conducted in accordance with the Declaration of Helsinki and approved by Shanghai Cancer Center ethics committees and institutional review boards.</p></div><div id="cam46762-sec-0022" class="tsec sec"><h2 class="head no_bottom_margin" id="cam46762-sec-0022title">PATIENT CONSENT STATEMENT</h2><p class="p p-first-last">All patients provided written informed consent for the analysis and anonymized publication of clinical data.</p></div><div id="notes-a.n.c" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.n.ctitle">Notes</h2><p>
<span class="mixed-citation" id="CAM46762-cit-2001">
Li D, Jin Y, Lin M, et al. <span class="ref-title">Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor&#x02010;positive, HER2&#x02010;negative metastatic breast cancer: A real&#x02010;world multicenter study</span>. <span class="ref-journal">Cancer Med</span>. 2024;<span class="ref-vol">13</span>:e6762. doi: 10.1002/cam4.6762
 [<a href="//doi.org/10.1002%2Fcam4.6762" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Med&amp;title=Treatment+patterns+and+clinical+outcomes+of+chidamide+combined+with+endocrine+therapy+in+hormone+receptor&#x02010;positive,+HER2&#x02010;negative+metastatic+breast+cancer:+A+real&#x02010;world+multicenter+study&amp;volume=13&amp;publication_year=2024&amp;pages=e6762&amp;doi=10.1002/cam4.6762&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span>
</p><p class="fn-group"><p class="fn sec" id="cam46762-note-0001">Doudou Li, Yizi Jin and Mingxi Lin have contributed equally to this work and share first authorship.</p></p></div><div id="cam46762aff-info" class="tsec sec"><h2 class="head no_bottom_margin" id="cam46762aff-infotitle">Contributor Information</h2><p><span class="fm-affl">Yanfei Liu, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="nc.ude.naduf@iefnayuil" class="oemail">nc.ude.naduf@iefnayuil</a></span>.</p><p><span class="fm-affl">Jian Zhang, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.361@0002renys" class="oemail">moc.361@0002renys</a></span>.</p></div><div id="cam46762-sec-0020" class="tsec bk-sec"><h2 class="head no_bottom_margin" id="cam46762-sec-0020title">DATA AVAILABILITY STATEMENT</h2><!--/article/back/sec/--><p class="p p-first-last">The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></div><div id="cam46762-bibl-0001" class="tsec sec"><h2 class="head no_bottom_margin" id="cam46762-bibl-0001title">REFERENCES</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0001">1. <span class="mixed-citation" id="cam46762-cit-0001">
Siegel RL, Miller KD, Jemal A. <span class="ref-title">Cancer statistics, 2020</span>. <span class="ref-journal">CA Cancer J Clin</span>. 2020;<span class="ref-vol">70</span>:7&#x02010;30. doi: 10.3322/caac.21590

 [<a href="https://pubmed.ncbi.nlm.nih.gov/31912902" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3322%2Fcaac.21590" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=CA+Cancer+J+Clin&amp;title=Cancer+statistics,+2020&amp;volume=70&amp;publication_year=2020&amp;pages=7-30&amp;pmid=31912902&amp;doi=10.3322/caac.21590&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0002">2. <span class="mixed-citation" id="cam46762-cit-0002">
DeSantis CE, Ma J, Gaudet MM, et&#x000a0;al. <span class="ref-title">
CA Cancer J Clin
</span>. 2019;<span class="ref-vol">69</span>:438&#x02010;451. doi: 10.3322/caac.21583
 [<a href="https://pubmed.ncbi.nlm.nih.gov/31577379" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3322%2Fcaac.21583" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar?q=&#10;+&#10;+DeSantis+&#10;+CE+&#10;+,++&#10;+Ma+&#10;+J+&#10;+,++&#10;+Gaudet+&#10;+MM+&#10;+,+et&#x000a0;al.++&#10;CA+Cancer+J+Clin&#10;+.++2019+;+69+:+438+&#x02010;+451+.+doi:+10.3322/caac.21583+&#10;+" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0003">3. <span class="mixed-citation" id="cam46762-cit-0003">
Yap YS, Lu YS, Tamura K, et&#x000a0;al. <span class="ref-title">Insights into breast cancer in the east vs the west: a review</span>. <span class="ref-journal">JAMA Oncol</span>. 2019;<span class="ref-vol">5</span>:1489&#x02010;1496. doi: 10.1001/jamaoncol.2019.0620

 [<a href="https://pubmed.ncbi.nlm.nih.gov/31095268" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1001%2Fjamaoncol.2019.0620" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA+Oncol&amp;title=Insights+into+breast+cancer+in+the+east+vs+the+west:+a+review&amp;volume=5&amp;publication_year=2019&amp;pages=1489-1496&amp;pmid=31095268&amp;doi=10.1001/jamaoncol.2019.0620&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0004">4. <span class="mixed-citation" id="cam46762-cit-0004">
Hanker AB, Sudhan DR, Arteaga CL. <span class="ref-title">Overcoming endocrine resistance in breast cancer</span>. <span class="ref-journal">Cancer Cell</span>. 2020;<span class="ref-vol">37</span>:496&#x02010;513. doi: 10.1016/j.ccell.2020.03.009

 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7169993/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32289273" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ccell.2020.03.009" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Cell&amp;title=Overcoming+endocrine+resistance+in+breast+cancer&amp;volume=37&amp;publication_year=2020&amp;pages=496-513&amp;pmid=32289273&amp;doi=10.1016/j.ccell.2020.03.009&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0005">5. <span class="mixed-citation" id="cam46762-cit-0005">
Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AMH. <span class="ref-title">Functional activation of the estrogen receptor&#x02010;&#x003b1; and aromatase by the HDAC inhibitor entinostat sensitizes ER&#x02010;negative tumors to letrozole</span>. <span class="ref-journal">Cancer Res</span>. 2011;<span class="ref-vol">71</span>:1893&#x02010;1903. doi: 10.1158/0008-5472.can-10-2458

 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3076193/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21245100" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.can-10-2458" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Functional+activation+of+the+estrogen+receptor&#x02010;&#x003b1;+and+aromatase+by+the+HDAC+inhibitor+entinostat+sensitizes+ER&#x02010;negative+tumors+to+letrozole&amp;volume=71&amp;publication_year=2011&amp;pages=1893-1903&amp;pmid=21245100&amp;doi=10.1158/0008-5472.can-10-2458&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0006">6. <span class="mixed-citation" id="cam46762-cit-0006">
Sabnis GJ, Goloubeva OG, Kazi AA, Shah P, Brodie AH. <span class="ref-title">HDAC inhibitor entinostat restores responsiveness of letrozole&#x02010;resistant MCF&#x02010;7Ca xenografts to aromatase inhibitors through modulation of Her&#x02010;2</span>. <span class="ref-journal">Mol Cancer Ther</span>. 2013;<span class="ref-vol">12</span>:2804&#x02010;2816. doi: 10.1158/1535-7163.mct-13-0345

 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3858401/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24092810" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.mct-13-0345" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=HDAC+inhibitor+entinostat+restores+responsiveness+of+letrozole&#x02010;resistant+MCF&#x02010;7Ca+xenografts+to+aromatase+inhibitors+through+modulation+of+Her&#x02010;2&amp;volume=12&amp;publication_year=2013&amp;pages=2804-2816&amp;pmid=24092810&amp;doi=10.1158/1535-7163.mct-13-0345&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0007">7. <span class="mixed-citation" id="cam46762-cit-0007">
Ning ZQ, Li ZB, Newman MJ, et&#x000a0;al. <span class="ref-title">Chidamide (CS055/HBI&#x02010;8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell&#x02010;mediated tumor cell cytotoxicity</span>. <span class="ref-journal">Cancer Chemother Pharmacol</span>. 2012;<span class="ref-vol">69</span>:901&#x02010;909. doi: 10.1007/s00280-011-1766-x

 [<a href="https://pubmed.ncbi.nlm.nih.gov/22080169" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs00280-011-1766-x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Chemother+Pharmacol&amp;title=Chidamide+(CS055/HBI&#x02010;8000):+a+new+histone+deacetylase+inhibitor+of+the+benzamide+class+with+antitumor+activity+and+the+ability+to+enhance+immune+cell&#x02010;mediated+tumor+cell+cytotoxicity&amp;volume=69&amp;publication_year=2012&amp;pages=901-909&amp;pmid=22080169&amp;doi=10.1007/s00280-011-1766-x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0008">8. <span class="mixed-citation" id="cam46762-cit-0008">
Shen L, Pili R. <span class="ref-title">Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy</span>. <span class="ref-journal">Onco Targets Ther</span>. 2012;<span class="ref-vol">1</span>:948&#x02010;950. doi: 10.4161/onci.20306
 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3489755/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23162767" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4161%2Fonci.20306" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Onco+Targets+Ther&amp;title=Class+I+histone+deacetylase+inhibition+is+a+novel+mechanism+to+target+regulatory+T+cells+in+immunotherapy&amp;volume=1&amp;publication_year=2012&amp;pages=948-950&amp;doi=10.4161/onci.20306&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0009">9. <span class="mixed-citation" id="cam46762-cit-0009">
Lin SH, Wang BY, Lin CH, et&#x000a0;al. <span class="ref-title">Chidamide alleviates TGF&#x02010;&#x003b2;&#x02010;induced epithelial&#x02010;mesenchymal transition in lung cancer cell lines</span>. <span class="ref-journal">Mol Biol Rep</span>. 2016;<span class="ref-vol">43</span>:687&#x02010;695. doi: 10.1007/s11033-016-4005-z

 [<a href="https://pubmed.ncbi.nlm.nih.gov/27188428" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs11033-016-4005-z" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Biol+Rep&amp;title=Chidamide+alleviates+TGF&#x02010;&#x003b2;&#x02010;induced+epithelial&#x02010;mesenchymal+transition+in+lung+cancer+cell+lines&amp;volume=43&amp;publication_year=2016&amp;pages=687-695&amp;pmid=27188428&amp;doi=10.1007/s11033-016-4005-z&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0010">10. <span class="mixed-citation" id="cam46762-cit-0010">
Zhang Q, Wang T, Geng C, et&#x000a0;al. <span class="ref-title">Exploratory clinical study of chidamide, an oral subtype&#x02010;selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor&#x02010;positive advanced breast cancer</span>. <span class="ref-journal">Chin J Cancer Res</span>. 2018;<span class="ref-vol">30</span>:605&#x02010;612. doi: 10.21147/j.issn.1000-9604.2018.06.05

 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6328505/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30700929" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.21147%2Fj.issn.1000-9604.2018.06.05" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Chin+J+Cancer+Res&amp;title=Exploratory+clinical+study+of+chidamide,+an+oral+subtype&#x02010;selective+histone+deacetylase+inhibitor,+in+combination+with+exemestane+in+hormone+receptor&#x02010;positive+advanced+breast+cancer&amp;volume=30&amp;publication_year=2018&amp;pages=605-612&amp;pmid=30700929&amp;doi=10.21147/j.issn.1000-9604.2018.06.05&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0011">11. <span class="mixed-citation" id="cam46762-cit-0011">
Jiang Z, Li W, Hu X, et&#x000a0;al. <span class="ref-title">Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor&#x02010;positive breast cancer (ACE): a randomised, double&#x02010;blind, placebo&#x02010;controlled, phase 3 trial</span>. <span class="ref-journal">Lancet Oncol</span>. 2019;<span class="ref-vol">20</span>:806&#x02010;815. doi: 10.1016/s1470-2045(19)30164-0

 [<a href="https://pubmed.ncbi.nlm.nih.gov/31036468" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fs1470-2045(19)30164-0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Oncol&amp;title=Tucidinostat+plus+exemestane+for+postmenopausal+patients+with+advanced,+hormone+receptor&#x02010;positive+breast+cancer+(ACE):+a+randomised,+double&#x02010;blind,+placebo&#x02010;controlled,+phase+3+trial&amp;volume=20&amp;publication_year=2019&amp;pages=806-815&amp;pmid=31036468&amp;doi=10.1016/s1470-2045(19)30164-0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0012">12. <span class="mixed-citation" id="cam46762-cit-0012">
Eisenhauer EA, Therasse P, Bogaerts J, et&#x000a0;al. <span class="ref-title">New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</span>. <span class="ref-journal">Eur J Cancer</span>. 2009;<span class="ref-vol">45</span>:228&#x02010;247. doi: 10.1016/j.ejca.2008.10.026

 [<a href="https://pubmed.ncbi.nlm.nih.gov/19097774" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ejca.2008.10.026" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Cancer&amp;title=New+response+evaluation+criteria+in+solid+tumours:+revised+RECIST+guideline+(version+1.1)&amp;volume=45&amp;publication_year=2009&amp;pages=228-247&amp;pmid=19097774&amp;doi=10.1016/j.ejca.2008.10.026&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0013">13. <span class="mixed-citation" id="cam46762-cit-0013">
Finn RS, Crown JP, Lang I, et&#x000a0;al. <span class="ref-title">The cyclin&#x02010;dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first&#x02010;line treatment of oestrogen receptor&#x02010;positive, HER2&#x02010;negative, advanced breast cancer (PALOMA&#x02010;1/TRIO&#x02010;18): a randomised phase 2 study</span>. <span class="ref-journal">Lancet Oncol</span>. 2015;<span class="ref-vol">16</span>:25&#x02010;35. doi: 10.1016/s1470-2045(14)71159-3

 [<a href="https://pubmed.ncbi.nlm.nih.gov/25524798" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fs1470-2045(14)71159-3" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Oncol&amp;title=The+cyclin&#x02010;dependent+kinase+4/6+inhibitor+palbociclib+in+combination+with+letrozole+versus+letrozole+alone+as+first&#x02010;line+treatment+of+oestrogen+receptor&#x02010;positive,+HER2&#x02010;negative,+advanced+breast+cancer+(PALOMA&#x02010;1/TRIO&#x02010;18):+a+randomised+phase+2+study&amp;volume=16&amp;publication_year=2015&amp;pages=25-35&amp;pmid=25524798&amp;doi=10.1016/s1470-2045(14)71159-3&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0014">14. <span class="mixed-citation" id="cam46762-cit-0014">
Finn RS, Martin M, Rugo HS, et&#x000a0;al. <span class="ref-title">Palbociclib and letrozole in advanced breast cancer</span>. <span class="ref-journal">N Engl J Med</span>. 2016;<span class="ref-vol">375</span>:1925&#x02010;1936. doi: 10.1056/NEJMoa1607303

 [<a href="https://pubmed.ncbi.nlm.nih.gov/27959613" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1056%2FNEJMoa1607303" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Palbociclib+and+letrozole+in+advanced+breast+cancer&amp;volume=375&amp;publication_year=2016&amp;pages=1925-1936&amp;pmid=27959613&amp;doi=10.1056/NEJMoa1607303&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0015">15. <span class="mixed-citation" id="cam46762-cit-0015">
Cristofanilli M, Turner NC, Bondarenko I, et&#x000a0;al. <span class="ref-title">Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone&#x02010;receptor&#x02010;positive, HER2&#x02010;negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA&#x02010;3): final analysis of the multicentre, double&#x02010;blind, phase 3 randomised controlled trial</span>. <span class="ref-journal">Lancet Oncol</span>. 2016;<span class="ref-vol">17</span>:425&#x02010;439. doi: 10.1016/s1470-2045(15)00613-0

 [<a href="https://pubmed.ncbi.nlm.nih.gov/26947331" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fs1470-2045(15)00613-0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Oncol&amp;title=Fulvestrant+plus+palbociclib+versus+fulvestrant+plus+placebo+for+treatment+of+hormone&#x02010;receptor&#x02010;positive,+HER2&#x02010;negative+metastatic+breast+cancer+that+progressed+on+previous+endocrine+therapy+(PALOMA&#x02010;3):+final+analysis+of+the+multicentre,+double&#x02010;blind,+phase+3+randomised+controlled+trial&amp;volume=17&amp;publication_year=2016&amp;pages=425-439&amp;pmid=26947331&amp;doi=10.1016/s1470-2045(15)00613-0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0016">16. <span class="mixed-citation" id="cam46762-cit-0016">
Hortobagyi GN, Stemmer SM, Burris HA, et&#x000a0;al. <span class="ref-title">Ribociclib as first&#x02010;line therapy for HR&#x02010;positive, advanced breast cancer</span>. <span class="ref-journal">N Engl J Med</span>. 2016;<span class="ref-vol">375</span>:1738&#x02010;1748. doi: 10.1056/NEJMoa1609709

 [<a href="https://pubmed.ncbi.nlm.nih.gov/27717303" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1056%2FNEJMoa1609709" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Ribociclib+as+first&#x02010;line+therapy+for+HR&#x02010;positive,+advanced+breast+cancer&amp;volume=375&amp;publication_year=2016&amp;pages=1738-1748&amp;pmid=27717303&amp;doi=10.1056/NEJMoa1609709&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0017">17. <span class="mixed-citation" id="cam46762-cit-0017">
Tripathy D, Im SA, Colleoni M, et&#x000a0;al. <span class="ref-title">Ribociclib plus endocrine therapy for premenopausal women with hormone&#x02010;receptor&#x02010;positive, advanced breast cancer (MONALEESA&#x02010;7): a randomised phase 3 trial</span>. <span class="ref-journal">Lancet Oncol</span>. 2018;<span class="ref-vol">19</span>:904&#x02010;915. doi: 10.1016/s1470-2045(18)30292-4

 [<a href="https://pubmed.ncbi.nlm.nih.gov/29804902" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fs1470-2045(18)30292-4" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Oncol&amp;title=Ribociclib+plus+endocrine+therapy+for+premenopausal+women+with+hormone&#x02010;receptor&#x02010;positive,+advanced+breast+cancer+(MONALEESA&#x02010;7):+a+randomised+phase+3+trial&amp;volume=19&amp;publication_year=2018&amp;pages=904-915&amp;pmid=29804902&amp;doi=10.1016/s1470-2045(18)30292-4&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0018">18. <span class="mixed-citation" id="cam46762-cit-0018">
Slamon DJ, Neven P, Chia S, et&#x000a0;al. <span class="ref-title">Phase III randomized study of ribociclib and fulvestrant in hormone receptor&#x02010;positive, human epidermal growth factor receptor 2&#x02010;negative advanced breast cancer: MONALEESA&#x02010;3</span>. <span class="ref-journal">J Clin Oncol</span>. 2018;<span class="ref-vol">36</span>:2465&#x02010;2472. doi: 10.1200/jco.2018.78.9909

 [<a href="https://pubmed.ncbi.nlm.nih.gov/29860922" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1200%2Fjco.2018.78.9909" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Phase+III+randomized+study+of+ribociclib+and+fulvestrant+in+hormone+receptor&#x02010;positive,+human+epidermal+growth+factor+receptor+2&#x02010;negative+advanced+breast+cancer:+MONALEESA&#x02010;3&amp;volume=36&amp;publication_year=2018&amp;pages=2465-2472&amp;pmid=29860922&amp;doi=10.1200/jco.2018.78.9909&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0019">19. <span class="mixed-citation" id="cam46762-cit-0019">
Hortobagyi GN, Stemmer SM, Burris HA, et&#x000a0;al. <span class="ref-title">Updated results from MONALEESA&#x02010;2, a phase III trial of first&#x02010;line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor&#x02010;positive, HER2&#x02010;negative advanced breast cancer</span>. <span class="ref-journal">Ann Oncol</span>. 2018;<span class="ref-vol">29</span>:1541&#x02010;1547. doi: 10.1093/annonc/mdy155

 [<a href="https://pubmed.ncbi.nlm.nih.gov/29718092" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fannonc%2Fmdy155" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Oncol&amp;title=Updated+results+from+MONALEESA&#x02010;2,+a+phase+III+trial+of+first&#x02010;line+ribociclib+plus+letrozole+versus+placebo+plus+letrozole+in+hormone+receptor&#x02010;positive,+HER2&#x02010;negative+advanced+breast+cancer&amp;volume=29&amp;publication_year=2018&amp;pages=1541-1547&amp;pmid=29718092&amp;doi=10.1093/annonc/mdy155&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0020">20. <span class="mixed-citation" id="cam46762-cit-0020">
Im SA, Lu YS, Bardia A, et&#x000a0;al. <span class="ref-title">Overall survival with ribociclib plus endocrine therapy in breast cancer</span>. <span class="ref-journal">N Engl J Med</span>. 2019;<span class="ref-vol">381</span>:307&#x02010;316. doi: 10.1056/NEJMoa1903765

 [<a href="https://pubmed.ncbi.nlm.nih.gov/31166679" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1056%2FNEJMoa1903765" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Overall+survival+with+ribociclib+plus+endocrine+therapy+in+breast+cancer&amp;volume=381&amp;publication_year=2019&amp;pages=307-316&amp;pmid=31166679&amp;doi=10.1056/NEJMoa1903765&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0021">21. <span class="mixed-citation" id="cam46762-cit-0021">
Slamon DJ, Neven P, Chia S, et&#x000a0;al. <span class="ref-title">Overall survival with ribociclib plus fulvestrant in advanced breast cancer</span>. <span class="ref-journal">N Engl J Med</span>. 2020;<span class="ref-vol">382</span>:514&#x02010;524. doi: 10.1056/NEJMoa1911149

 [<a href="https://pubmed.ncbi.nlm.nih.gov/31826360" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1056%2FNEJMoa1911149" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Overall+survival+with+ribociclib+plus+fulvestrant+in+advanced+breast+cancer&amp;volume=382&amp;publication_year=2020&amp;pages=514-524&amp;pmid=31826360&amp;doi=10.1056/NEJMoa1911149&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0022">22. <span class="mixed-citation" id="cam46762-cit-0022">
Sledge GW Jr, Toi M, Neven P, et&#x000a0;al. <span class="ref-title">MONARCH 2: Abemaciclib in combination with Fulvestrant in women with HR+/HER2&#x02010; advanced breast cancer who had progressed while receiving endocrine therapy</span>. <span class="ref-journal">J Clin Oncol</span>. 2017;<span class="ref-vol">35</span>:2875&#x02010;2884. doi: 10.1200/jco.2017.73.7585

 [<a href="https://pubmed.ncbi.nlm.nih.gov/28580882" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1200%2Fjco.2017.73.7585" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=MONARCH+2:+Abemaciclib+in+combination+with+Fulvestrant+in+women+with+HR+/HER2&#x02010;+advanced+breast+cancer+who+had+progressed+while+receiving+endocrine+therapy&amp;volume=35&amp;publication_year=2017&amp;pages=2875-2884&amp;pmid=28580882&amp;doi=10.1200/jco.2017.73.7585&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0023">23. <span class="mixed-citation" id="cam46762-cit-0023">
Goetz MP, Toi M, Campone M, et&#x000a0;al. <span class="ref-title">MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer</span>. <span class="ref-journal">J Clin Oncol</span>. 2017;<span class="ref-vol">35</span>:3638&#x02010;3646. doi: 10.1200/jco.2017.75.6155

 [<a href="https://pubmed.ncbi.nlm.nih.gov/28968163" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1200%2Fjco.2017.75.6155" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=MONARCH+3:+Abemaciclib+as+initial+therapy+for+advanced+breast+cancer&amp;volume=35&amp;publication_year=2017&amp;pages=3638-3646&amp;pmid=28968163&amp;doi=10.1200/jco.2017.75.6155&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0024">24. <span class="mixed-citation" id="cam46762-cit-0024">
Sledge GW Jr, Toi M, Neven P, et&#x000a0;al. <span class="ref-title">The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor&#x02010;positive, ERBB2&#x02010;negative breast cancer that progressed on endocrine therapy&#x02010;MONARCH 2: a randomized clinical trial</span>. <span class="ref-journal">JAMA Oncol</span>. 2020;<span class="ref-vol">6</span>:116&#x02010;124. doi: 10.1001/jamaoncol.2019.4782

 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6777264/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31563959" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1001%2Fjamaoncol.2019.4782" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA+Oncol&amp;title=The+effect+of+abemaciclib+plus+fulvestrant+on+overall+survival+in+hormone+receptor&#x02010;positive,+ERBB2&#x02010;negative+breast+cancer+that+progressed+on+endocrine+therapy&#x02010;MONARCH+2:+a+randomized+clinical+trial&amp;volume=6&amp;publication_year=2020&amp;pages=116-124&amp;pmid=31563959&amp;doi=10.1001/jamaoncol.2019.4782&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0025">25. <span class="mixed-citation" id="cam46762-cit-0025">
Xu B, Zhang Q, Zhang P, et&#x000a0;al. <span class="ref-title">Dalpiciclib or placebo plus fulvestrant in hormone receptor&#x02010;positive and HER2&#x02010;negative advanced breast cancer: a randomized, phase 3 trial</span>. <span class="ref-journal">Nat Med</span>. 2021;<span class="ref-vol">27</span>:1904&#x02010;1909. doi: 10.1038/s41591-021-01562-9

 [<a href="https://pubmed.ncbi.nlm.nih.gov/34737452" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41591-021-01562-9" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Med&amp;title=Dalpiciclib+or+placebo+plus+fulvestrant+in+hormone+receptor&#x02010;positive+and+HER2&#x02010;negative+advanced+breast+cancer:+a+randomized,+phase+3+trial&amp;volume=27&amp;publication_year=2021&amp;pages=1904-1909&amp;pmid=34737452&amp;doi=10.1038/s41591-021-01562-9&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0026">26. <span class="mixed-citation" id="cam46762-cit-0026">
Li Y, Li W, Gong C, et&#x000a0;al. <span class="ref-title">A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2&#x02010; metastatic breast cancer</span>. <span class="ref-journal">Ther Adv Med Oncol</span>. 2021;<span class="ref-vol">13</span>:17588359211022890. doi: 10.1177/17588359211022890

 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8202336/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34178122" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1177%2F17588359211022890" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ther+Adv+Med+Oncol&amp;title=A+multicenter+analysis+of+treatment+patterns+and+clinical+outcomes+of+subsequent+therapies+after+progression+on+palbociclib+in+HR+/HER2&#x02010;+metastatic+breast+cancer&amp;volume=13&amp;publication_year=2021&amp;pages=17588359211022890&amp;pmid=34178122&amp;doi=10.1177/17588359211022890&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0027">27. <span class="mixed-citation" id="cam46762-cit-0027">
Li Y, Mo H, Guan X, et&#x000a0;al. <span class="ref-title">Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor&#x02010;positive, HER2&#x02010;negative metastatic breast cancer: a study of the National Cancer Center, China</span>. <span class="ref-journal">Breast</span>. 2022;<span class="ref-vol">61</span>:129&#x02010;135. doi: 10.1016/j.breast.2021.12.017

 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8741603/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34995922" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.breast.2021.12.017" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast&amp;title=Real+world+initial+palliative+treatment+patterns+and+clinical+outcomes+in+premenopausal+patients+with+hormone+receptor&#x02010;positive,+HER2&#x02010;negative+metastatic+breast+cancer:+a+study+of+the+National+Cancer+Center,+China&amp;volume=61&amp;publication_year=2022&amp;pages=129-135&amp;pmid=34995922&amp;doi=10.1016/j.breast.2021.12.017&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0028">28. <span class="mixed-citation" id="cam46762-cit-0028">
Bonotto M, Gerratana L, Di Maio M, et&#x000a0;al. <span class="ref-title">Chemotherapy versus endocrine therapy as first&#x02010;line treatment in patients with luminal&#x02010;like HER2&#x02010;negative metastatic breast cancer: a propensity score analysis</span>. <span class="ref-journal">Breast</span>. 2017;<span class="ref-vol">31</span>:114&#x02010;120. doi: 10.1016/j.breast.2016.10.021

 [<a href="https://pubmed.ncbi.nlm.nih.gov/27837704" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.breast.2016.10.021" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast&amp;title=Chemotherapy+versus+endocrine+therapy+as+first&#x02010;line+treatment+in+patients+with+luminal&#x02010;like+HER2&#x02010;negative+metastatic+breast+cancer:+a+propensity+score+analysis&amp;volume=31&amp;publication_year=2017&amp;pages=114-120&amp;pmid=27837704&amp;doi=10.1016/j.breast.2016.10.021&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0029">29. <span class="mixed-citation" id="cam46762-cit-0029">
Munster PN, Thurn KT, Thomas S, et&#x000a0;al. <span class="ref-title">A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy&#x02010;resistant breast cancer</span>. <span class="ref-journal">Br J Cancer</span>. 2011;<span class="ref-vol">104</span>:1828&#x02010;1835. doi: 10.1038/bjc.2011.156

 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3111195/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21559012" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fbjc.2011.156" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Cancer&amp;title=A+phase+II+study+of+the+histone+deacetylase+inhibitor+vorinostat+combined+with+tamoxifen+for+the+treatment+of+patients+with+hormone+therapy&#x02010;resistant+breast+cancer&amp;volume=104&amp;publication_year=2011&amp;pages=1828-1835&amp;pmid=21559012&amp;doi=10.1038/bjc.2011.156&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0030">30. <span class="mixed-citation" id="cam46762-cit-0030">
Yardley DA, Ismail&#x02010;Khan RR, Melichar B, et&#x000a0;al. <span class="ref-title">Randomized phase II, double&#x02010;blind, placebo&#x02010;controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor&#x02010;positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor</span>. <span class="ref-journal">J Clin Oncol</span>. 2013;<span class="ref-vol">31</span>:2128&#x02010;2135. doi: 10.1200/jco.2012.43.7251

 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4881332/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23650416" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1200%2Fjco.2012.43.7251" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Randomized+phase+II,+double&#x02010;blind,+placebo&#x02010;controlled+study+of+exemestane+with+or+without+entinostat+in+postmenopausal+women+with+locally+recurrent+or+metastatic+estrogen+receptor&#x02010;positive+breast+cancer+progressing+on+treatment+with+a+nonsteroidal+aromatase+inhibitor&amp;volume=31&amp;publication_year=2013&amp;pages=2128-2135&amp;pmid=23650416&amp;doi=10.1200/jco.2012.43.7251&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="cam46762-bib-0031">31. <span class="mixed-citation" id="cam46762-cit-0031">
Shi Y, Dong M, Hong X, et&#x000a0;al. <span class="ref-title">Results from a multicenter, open&#x02010;label, pivotal phase II study of chidamide in relapsed or refractory peripheral T&#x02010;cell lymphoma</span>. <span class="ref-journal">Ann Oncol</span>. 2015;<span class="ref-vol">26</span>:1766&#x02010;1771. doi: 10.1093/annonc/mdv237

 [<a href="https://pubmed.ncbi.nlm.nih.gov/26105599" ref="reftype=pubmed&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fannonc%2Fmdv237" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Oncol&amp;title=Results+from+a+multicenter,+open&#x02010;label,+pivotal+phase+II+study+of+chidamide+in+relapsed+or+refractory+peripheral+T&#x02010;cell+lymphoma&amp;volume=26&amp;publication_year=2015&amp;pages=1766-1771&amp;pmid=26105599&amp;doi=10.1093/annonc/mdv237&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10923034&amp;issue-id=457477&amp;journal-id=1974&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">Cancer Medicine</span> are provided here courtesy of <strong>Wiley</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10923034/pdf/CAM4-13-e6762.pdf" class="int-view">PDF (1.0M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10923034/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10923034/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10923034" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10923034%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="IrYGrKVQXU9T6cDP4tq2f6PgWt6nZdM2DZR6b2YC9oJy9keLfJ7Qd2vOCRmaFKKc">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10923034%2F&amp;text=Treatment%20patterns%20and%20clinical%20outcomes%20of%20chidamide%20combined%20with%20endocrine%20therapy%20in%20hormone%20receptor%02010positive%2C%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10923034%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923034/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10923034/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/38457252/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10923034/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/38457252/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10923034/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10923034/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC10923034/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
